The 6 most recent market catalysts affecting $ACIU, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response
AC Immune reported that its Parkinson's drug, ACI-7104, met all primary endpoints in Part 1 of its Phase 2 trial, demonstrating 100% antibody response and good safety. This is a si…
Sep 23, 2026
Corporate Catalyst
Bullish
Impact 75
AC Immune Announces Safety And Immunogenicity Results Through Week 100 In Part 1 Of VacSYn, Its Phase 2 Trial Of ACI-7104 In Patients With Early-Stage Parkinson’s Disease: All Primary Endpoints Were Met, Generally Safe And Well Tolerated; Strong Immunogenicity Demonstrated, With 100% Response Rate After Three Immunizations
AC Immune (ACIU) reported that Part 1 of its Phase 2 VacSYn trial for ACI-7104 in early-stage Parkinson's disease met all primary endpoints for safety, tolerability, and immunogeni…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 65
AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline
AC Immune (ACIU) has reported positive interim Phase 1 data for ACI-19764, an anti-inflammatory drug. This is a significant development as the drug showed safety, tolerability, bra…
Aug 20, 2026
Corporate Catalyst
Bullish
Impact 75
AC Immune Says NLRP3 Inhibitor ACI-19764 Safe And Well Tolerated In Phase 1 With Confirmed CSF Penetration; Initial Cardiovascular Risk Cohort Results Expected By Year End
The positive Phase 1 results for ACI-19764, particularly the confirmed CSF penetration, are a significant de-risking event for AC Immune. This data suggests the drug can reach its …
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 75
AC Immune Says FDA Grants Fast Track Designation And IND Clearance For Anti-Alpha-Synuclein Immunotherapy ACI-7104 In Early Parkinson's; Phase 2 VacSYn Week-100 Data Expected In H2 2026
The FDA's Fast Track designation for ACI-7104 is a significant positive for AC Immune, as it expedites the development and review process for drugs addressing serious conditions wi…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 55
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
BTIG analyst Thomas Shrader has reiterated a 'Buy' rating and an $8 price target for AC Immune (ACIU). This action signifies that the analyst maintains a positive outlook on the co…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.